Table S1.
Clinical and histopathological classification of subjects
| ID | Pathology diagnosis | Age, y | M/F | WBC | DEX | PTEN (IHC) | p53 (IHC) | EGFR (IHC) | EGFR vIII | IDH1 R132H | MGMT methyl. |
| N01 | Nonneoplastic (normal cortex) | 79 | M | 6.2 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| N02 | Nonneoplastic (normal cortex) | 45 | M | 9.5 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| N03 | Nonneoplastic (diffuse amyloid, consistent with aging) | 80 | M | 8.4 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |
| L04 | Astrocytoma, grade II | 33 | F | 4.5 | 0 | − | − | (+) | N/A | − | N/A |
| L05 | Oligodendroglioma, grade II | 59 | F | 8.3 | 0 | (+) | − | (+) | N/A | + | N/A |
| L06 | Oligodendroglioma, grade II | 25 | M | 15.8 | 5 | (+) | (+) | + | − | + | + |
| G07 | Glioblastoma, grade IV | 67 | M | 17.2 | 4 | (+) | + | + | + | − | + |
| G08 | Glioblastoma, oligodendroglial component, grade IV | 68 | M | 13.3 | 1 | (+) | (+) | + | − | + | + |
| G09 | Glioblastoma, grade IV | 57 | M | 9.4 | 0 | +/− | + | + | − | − | − |
| G10 | Glioblastoma, oligodendroglial component, grade IV | 36 | M | 16.7 | 0 | (+) | − | + | − | + | + |
| G11 | Glioblastoma, grade IV | 53 | M | 14.2 | 5 | (+) | + | + | − | − | N/A |
| G12 | Glioblastoma, grade IV | 78 | F | 18.2 | 1 | (+) | (+) | + | − | + | + |
| G13 | Glioblastoma, grade IV | 53 | M | 11.4 | 1 | − | (+) | + | − | − | N/A |
| G14 | Glioblastoma, grade IV | 60 | F | 12.1 | 1 | (+) | + | + | − | − | + |
| H15 | None (healthy subject) | 57 | M | N/A | N/A | PBMC only | |||||
DEX: Days on dexamethasone steroid therapy before surgery. Immunohistochemistry (IHC) and PCR genotyping were performed through the Department of Pathology at New York Presbyterian Hospital per diagnostic standards. EGFR (epidermal growth factor receptor) expression by IHC: + expression, (+) weak expression, − no expression. EGFRvIII (truncation mutation) by PCR: + mutation detected, − no vIII mutation detected. IDH1-R132H (isocitrate dehydrogenase R132H point mutation) by IHC: (+) mutation detected, (−) mutation not detected. M/F: male/female. MGMT (O6-methylguanine-DNA methyltransferase) gene promoter methylation by bisulfite DNA sequencing: + methylation detected, − methylation not detected. N/A, data not available. PTEN (phosphatase and tensin homolog) expression by IHC: + positive, − negative, (+) weak positive, +/− mixture. p53 (expression) by IHC: + positive, − negative, (+) weak positive. WBC: white blood cell count, performed by clinical laboratory at New York Presbyterian Hospital on the day of or day before surgery for glioma patients, up to 1 wk prior for nonneoplastic patients.